Sun Pharmaceutical Industries Limited announced in a stock exchange filing the outcomes of a Phase 1 study assessing GL0034 (Utreglutide) in obese adults. Presented at the 84th Scientific Sessions of the American Diabetes Association (ADA) on June 21, 2024, in Orlando, FL, the study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics. The company stated that obesity …